Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
Quick Look: Pfizer’s Prevenar 20 will be included in Japan’s routine vaccination program for 65-year-olds from April, expanding its NIP use beyond children and replacing the long-used PPSV23. The company is stepping up awareness efforts to address low vaccination rates…
To read the full story
Related Article
- Japan Drops Transitional Plan for PCV20 Routine Shot in Elderly
December 23, 2025
- Japan Panel OKs PCV20 as Routine Pneumococcal Shot for Elderly
October 27, 2025
- Japan Panel Backs Shift to PCV20 for Pneumococcal Vaccination in Elderly
July 8, 2025
- Pfizer Rolls Out Prevenar 20 in Japan, Pediatric NIP Set to Start October
September 2, 2024
BUSINESS
- Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
- Samsca Generics Extend Label to ADPKD
April 21, 2026
- ASKA Ups Stake in MedChoice Parent to Deepen Philippines Tie-Up
April 21, 2026
- Nxera Bags US$10 Million Milestone from AbbVie in Neuro Collaboration
April 21, 2026
- Asahi Kasei Closes Aicuris Buy, Eyes US$500 Million Sales by 2030
April 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…